Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials
GlaxoSmithKline (United States) · Research Triangle Park Foundation · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
731
total citations
- FWCI
- 80.03
- Percentile
- 100%
- References
- 31
Citations per year
Authors
5- SPSteven PascoeCorresponding
GlaxoSmithKline (United States), Research Triangle Park Foundation
- NLNicholas Locantore
GlaxoSmithKline (United States), Research Triangle Park Foundation
- MTMark T. Dransfield
Birmingham VA Medical Center, University of Alabama at Birmingham
- NBNeil Barnes
William Harvey Research Institute, GlaxoSmithKline (United Kingdom)
- IPIan Pavord
University of Oxford
Topics & keywords
Topics
Keywords
- Medicine
- Fluticasone propionate
- Exacerbation
- COPD
- Fluticasone
- Internal medicine
- Eosinophil
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.